Kodiak Sciences Inc Common Stock

KODNASDAQ • USD
97.90 USD
↗ 0.09 (0.09%)AT CLOSE (03:59 PM EST)
98.01
↗ 0.11 (0.11%)
POST MARKET (AS OF 07:30 PM EST)
Post Market
AS OF 07:30 PM EST
98.01
↗ 0.11 (0.11%)
🔴Market: CLOSED

Kodiak Sciences Inc Common Stock (KOD) is currently trading at $97.99. The technical outlook is "Buy" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Nov 19, 2026.

Open?$99.09
High?$101.24
Low?$95.76
Prev. Close?$97.81
Volume?521.9K
Avg. Volume?1.0M
VWAP?$98.14
Rel. Volume?0.51x
Bid / Ask
Bid?$97.00 × 100
Ask?$103.00 × 100
Spread?$6.00
Midpoint?$100.00
Valuation & Ratios
Market Cap?6.4B
Shares Out?62.8M
Float?29.6M
Float %?47.1%
P/E Ratio?N/A
P/B Ratio?508.78
EPS?-$3.77
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Employees
124
Market Cap
6.4B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2018-10-04
Address
1250 PAGE MILL RD
PALO ALTO, CA 94304
Phone: 650-281-0850
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
92
Momentum?
50
Short Sent.?
36
Piotroski F-Score?0/9Weak
Altman Z-Score?4.07Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?27.42%Squeeze Risk
Short Interest?8.1M
Days to Cover?9.3
Free Float29.6M
Avg Daily Volume868.9K
Settlement Date2026-10-30
Financial Health
Current Ratio?1.70Adequate
Quick Ratio?1.70Adequate
Cash Ratio?1.62Strong
Debt/Equity?0.07Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
508.78HIGH▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-26.9CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-1,962.8%WEAK▾
ROA?
S&P
3
-117.8%WEAK▾
Cash Flow & Enterprise
FCF?$-172807000
Enterprise Value?$6.3B
Fundamentals ratios updated end of day